Pharmaceuticals 11 February 2026 - 14 February 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares moved higher on Tuesday. The stock outperformed biotech funds, which took a hit, as investors focused on upcoming management meetings and stayed active trading Ligand’s pending XOMA Royalty deal. The Nasdaq-listed stock was trading at $233.11 as of 12:53 p.m. EDT, up 1.4%. The SPDR S&P Biotech ETF was down 3.8% and the iShares Nasdaq Biotechnology ETF slid 3.0%. The SPY ETF, which tracks the S&P 500, edged up 0.1% and the QQQ, which follows the Nasdaq 100, added 0.4%.
June 2, 2026
Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer
···

Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer

New York, Feb 12, 2026, 16:23 EST — After-hours Merck & Co finished almost flat on Thursday, wiping out earlier gains, after the FDA signed off on a Keytruda combo for certain patients with platinum-resistant ovarian cancer—a form that recurs within six months after platinum chemo. Shares slipped 0.03% to $119.28, swinging between $118.18 and $121.62 over the session.
February 12, 2026
Evommune stock price slips premarket after 71% jump on eczema drug data
···

Evommune stock price slips premarket after 71% jump on eczema drug data

NEW YORK, Feb 11, 2026, 05:17 EST — Premarket Evommune, Inc. saw its shares slip roughly 1.6% in premarket trading Wednesday, down to $28.55. This comes after the clinical-stage biotech surged 70.9% the day before on promising mid-stage eczema trial results. On Tuesday, the stock closed at $29.03, having fluctuated between $21.80 and $33.20, putting it near the peak of its 52-week range.
February 11, 2026
1 2 3 4